This article is more than 5 years old. Information may no longer be current.
Trio Health presents novel HBV, HCV therapy findings at The Liver Meeting
Click Here to Manage Email Alerts
Trio Health presented results from four studies at The Liver Meeting 2019 that showed novel outcomes in patients treated for hepatitis B with Vemlidy or hepatitis C with Vosevi.
“Since our initial HCV studies in 2013, we’ve observed repeating themes across diseases where new, more efficacious, and safer therapies have been approved; namely, challenges in access to these therapies, understanding potential effects of long-term treatment with newer therapies, and potential concerns with the use of these therapies in diseases with changing population demographics,” Scott Milligan, PhD, head of analytics at Trio Health, said in a press release.
In a follow-up study of patients switching to Vemlidy (tenofovir alafenamide, or TAF, Gilead Sciences) therapy due to safety or side effects from other treatments, researchers found that the presence of osteoporosis, and suboptimal estimated glomerular filtration rate (eGFR), alanine aminotransferase or Fibrosis-4 index did not correlate with TAF adoption. This, according to the researchers, suggested that prevention rather than observation of detrimental clinical measures account for most cases of TAF adoption.
Another HBV study focused on long-term treatment (48 weeks or more) with TAF therapy. Patients demonstrated improvements in HBV DNA suppression (3.2%; P = .011) and mean ALT (–15.1%; P = .013) from baseline and improvements in eGFR among the 22% of patients with renal impairment.
Results from a retreatment study of patients who failed to achieve sustained virologic response with interferon-free direct-acting antivirals showed higher intention-to-treat (94% vs. 84%; P = .017) and per-protocol (98% vs. 85%; P < .001) SVR rates with Vosevi (sofosbuvir/velpatasvir/voxilaprevir or SOF/VEL/VOX, Gilead Sciences) compared with Mavyret (glecaprevir/pibrentasvir, AbbVie), including after adjusting for clinical differences for intention-to-treat (97% vs. 85%; P = .048) and per-protocol (100% vs. 85%; P = .012).
Finally, a study investigating drug-drug interactions with pangenotypic DAAs using two different data sources revealed potential interactions in 41% of patients prescribed glecaprevir/pibrentasvir, 27% prescribed Epclusa (sofosbuvir/velpatasvir, Gilead Sciences), and 53% prescribed SOF/VEL/VOX. Researchers noted, however, that pharmacist recommendations were not followed for 15% of patients.
Reference:
Curry M. Abstract 0486. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.
Curry M. Abstract 1503. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.
Flamm SL. Abstract 1500. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.
Reddy RK M. Abstract 0487. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.